Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An update on TGN1412.

Nirmala Bhogal1, Robert Combes

  • 1FRAME, Nottingham, NG1 4EE, UK. Nirmala@frame.org.uk

Alternatives to Laboratory Animals : ATLA
|July 13, 2006
PubMed
Summary
This summary is machine-generated.

Current methods for assessing new medicines, like humanised therapeutic agents, may be inadequate. This update reviews the TGN1412 clinical trial and its implications for drug safety testing protocols.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 0, including microdosing approaches: Applying the Three Rs and increasing the efficiency of human drug development.

Alternatives to laboratory animals : ATLA·2019
Same author

No time like the present - two hundred years of Parkinson's disease.

Alternatives to laboratory animals : ATLA·2017
Same author

Animal experimentation and alternatives: revealed preferences.

Alternatives to laboratory animals : ATLA·2017
Same author

Animal experimentation: the statistics speak for themselves.

Alternatives to laboratory animals : ATLA·2017
Same author

An approach to minimise dog use in regulatory toxicology: production of a best practice guide to study design.

Alternatives to laboratory animals : ATLA·2013
Same author

New technology for toxicity testing.

Advances in experimental medicine and biology·2012
Same journal

Conference Diary.

Alternatives to laboratory animals : ATLA·2026
Same journal

Spotlight on Three Rs Progress.

Alternatives to laboratory animals : ATLA·2026
Same journal

Resources Round-up.

Alternatives to laboratory animals : ATLA·2026
Same journal

Editorial.

Alternatives to laboratory animals : ATLA·2026
Same journal

<i>Galleria mellonella</i> as an invertebrate screening model for biocompatibility and <i>in vivo</i> functionality testing of imaging contrast agents.

Alternatives to laboratory animals : ATLA·2026
Same journal

Data-driven science, ethics and risk: Building knowledge of key ethics-risk intersections relevant to public sector decision-making.

Alternatives to laboratory animals : ATLA·2026
See all related articles

Area of Science:

  • Pharmacology and Toxicology
  • Immunology
  • Clinical Trial Design

Background:

  • Previous assessment in ATLA questioned the adequacy of existing safety and efficacy testing for humanised therapeutic agents.
  • The TGN1412 first-in-man study highlighted potential deficiencies in current drug development and testing paradigms.
  • Expert opinions and industry feedback were gathered following the TGN1412 incident.

Purpose of the Study:

  • To provide an update on the events surrounding the TGN1412 clinical trial.
  • To re-evaluate the suitability of current safety and efficacy assessment methods for novel therapeutic agents.
  • To inform ongoing discussions on preventing future adverse events in clinical trials.

Main Methods:

  • Review of the TGN1412 clinical trial events and outcomes.

Related Experiment Videos

  • Analysis of expert feedback and submissions regarding drug safety testing.
  • Assessment of existing regulatory and scientific methodologies for therapeutic agent evaluation.

    • Main Results:

    • The TGN1412 trial revealed significant safety concerns with the tested humanised therapeutic agent.
    • Existing preclinical and clinical testing models may not fully predict the in vivo behavior of certain novel drugs.
    • The incident prompted a review of safety assessment strategies by regulatory bodies and industry experts.

    Conclusions:

    • There is a critical need to refine and potentially develop new methods for assessing the safety and efficacy of humanised therapeutic agents.
    • The TGN1412 trial serves as a crucial case study for improving future drug development and clinical trial oversight.
    • Enhanced regulatory scrutiny and improved predictive preclinical models are essential for patient safety in novel drug development.